<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82763">
  <stage>Registered</stage>
  <submitdate>15/04/2008</submitdate>
  <approvaldate>17/04/2008</approvaldate>
  <actrnumber>ACTRN12608000207314</actrnumber>
  <trial_identification>
    <studytitle>The effect of red wine consumption on Cytochrome P450 metabolites of arachidonic acid</studytitle>
    <scientifictitle>The effect of alcohol and polyphenol consumption on Cytochrome P450 metabolites of arachidonic acid</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alcohol and polyphenol consumption on Cytochrome P450 metabolites</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Men who drink 40g of alcohol/day will be invited to participate in a 12 week trial of randomized block design, during which they will substitute the alcohol they drink for either 375 mol of water, or the equvalent volume of de-alcoholised red wine or red wine each for 4 weeks in crossover design without washout periods.</interventions>
    <comparator>The de-alcoholised red wine is the control for the red wine. The water is the control for the de-alcoholised red wine.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in Cytochrome P450 metabolites of Arachidonic acid in urine, plasma, cell membranes. between the treatments will be assessed using gas chromatography mass spectrometry</outcome>
      <timepoint>4, 8, and 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in ambulatory Blood pressure. between the treatments</outcome>
      <timepoint>4,8,and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma and urinary F2-isoprostanes measured using gas chromatography mass spectrometry</outcome>
      <timepoint>4,8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Resolvins</outcome>
      <timepoint>4,8, and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>alcohol consumption &gt;30g/day&lt;110g/day, non-smokers, not taking medication</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>smoking, alcohol consumption &lt;30g/day or &gt;110g/day. Taking medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central allocation by a statistician not involved in the trial</concealment>
    <sequence>block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>three period open label crossover study</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>21/04/2008</anticipatedstartdate>
    <actualstartdate>21/04/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/02/2009</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>22</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Austrlaia</primarysponsorname>
    <primarysponsoraddress>Stirling Hwy,
Nedlands
Western Australia 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NH&amp;MRC</fundingname>
      <fundingaddress>National Health &amp; Medical Research Council
20 Allara St, Canberra. ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Perth Hospital</sponsorname>
      <sponsoraddress>Wellington Street
Perth,6001</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The intervention trial is completed and is being analysed.
The primary purpose of the study was to compare the effect of drinking red wine or de-alcoholised red wine on blood pressure and fatty acid metabolites involved in blood pressure regulation. This study specifically tests the effect of the alcohol in red wine compared with the polyphenols in red wine.</summary>
    <trialwebsite />
    <publication>Publications are in preparation</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Univeristy of Western Australia</ethicname>
      <ethicaddress>Stirling Hwy,
Nedlands
Western Australia 6009</ethicaddress>
      <ethicapprovaldate>20/12/2006</ethicapprovaldate>
      <hrec>RA/4/1/1661</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Wellington Street
Perth,6001</ethicaddress>
      <ethicapprovaldate>26/02/2007</ethicapprovaldate>
      <hrec>RA-07/003</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr Anne Barden</name>
      <address>School of Medicine &amp; Pharmacology,
GPO BOX X2213 Perth, Western Australia</address>
      <phone>089224 0272</phone>
      <fax>089224 0246</fax>
      <email>anne.barden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Kevin Croft</name>
      <address>School of Medicine &amp; Pharmacology,
GPO BOX X2213 Perth, Western Australia</address>
      <phone>08 92240275</phone>
      <fax>0892240246</fax>
      <email>kevin.croft@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Anne Barden</name>
      <address>School of Medicine &amp; Pharmacology,
GPO BOX X2213 Perth, Western Australia</address>
      <phone>089224 0272</phone>
      <fax>089224 0246</fax>
      <email>anne.barden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Kevin Croft</name>
      <address>School of Medicine &amp; Pharmacology, GPO BOX X2213 Perth, Western Australia</address>
      <phone>618 9224 0275</phone>
      <fax />
      <email>kevin.croft@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>